Drug Trial Radar · NCT07227818
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Dec 16, 2025
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Conditions
- Schizophrenia
Interventions
NBI-1117568Drug
Oral capsules
PlaceboDrug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to RelapseTime frame: Up to approximately 30 weeks
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Garden Grove, California · Recruiting
Neurocrine Clinical Site
La Habra, California · Recruiting
Neurocrine Clinical Site
Lemon Grove, California · Recruiting
Neurocrine Clinical Site
Oceanside, California · Recruiting
Neurocrine Clinical Site
Torrance, California · Recruiting
Neurocrine Clinical Site
West Hills, California · Completed
Neurocrine Clinical Site
Hollywood, Florida · Recruiting
Neurocrine Clinical Site
Maitland, Florida · Recruiting
Neurocrine Clinical Site
Miami, Florida · Recruiting
Neurocrine Clinical Site
Miami, Florida · Recruiting
Neurocrine Clinical Site
Tampa, Florida · Recruiting
Neurocrine Clinical Site
West Palm Beach, Florida · Recruiting
Neurocrine Clinical Site
Atlanta, Georgia · Recruiting
Neurocrine Clinical Site
Boston, Massachusetts · Recruiting
Neurocrine Clinical Site
Flowood, Mississippi · Recruiting
Neurocrine Clinical Site
Marlton, New Jersey · Recruiting
Neurocrine Clinical Site
Cedarhurst, New York · Recruiting
Neurocrine Clinical Site
New York, New York · Recruiting
Neurocrine Clinical Site
New York, New York · Withdrawn
Neurocrine Clinical Site
The Bronx, New York · Recruiting
Neurocrine Clinical Site
DeSoto, Texas · Recruiting
Neurocrine Clinical Site
Bellevue, Washington · Recruiting
Neurocrine Clinical Site
San Juan, Puerto Rico · Recruiting
Neurocrine Clinical Site
Gornja Toponica, Serbia · Recruiting
Neurocrine Clinical Site
Kragujevac, Serbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.